Luminnova ImmuneDefense™ Program
The Background and Experience Behind the Program
The Luminnova ImmuneDefense™ Program was developed by Dr. Juliette Hepburn, drawing on more than ten years of clinical experience in the management of viral infections, particularly during the COVID-19 pandemic.
Early Experience with Photodynamic Therapy
During the early stages of the COVID-19 pandemic, Dr. Hepburn co-authored a scientific publication with a German colleague exploring the use of photodynamic therapy (PDT) in the nose and mouth.
This approach combined topical methylene blue with red light of a specific wavelength and produced highly successful clinical results. However, because the treatment initially required a laser as its light source, it had to be administered in a medical facility—a significant practical limitation, particularly during a pandemic.
Recognizing the need for a more accessible solution, Dr. Hepburn developed a portable oral/nasal LED device that enabled patients to administer treatment themselves at home, under remote medical supervision.
This home-based approach also proved highly successful, with rapid recovery observed in patients with COVID-19.
Adapting Treatment During the Delta Wave
Dr. Hepburn subsequently received approval from the Bahamas COVID-19 Ethics Committee to formally evaluate this treatment approach.
However, approval coincided with the emergence of the particularly severe Delta wave. Faced with substantially higher viral loads and more severe clinical presentations, it soon became apparent that the original treatment protocol was no longer sufficient.
In response, Dr. Hepburn refined the treatment schedule and introduced oral methylene blue capsules as an additional component.
This proved to be a turning point.
The addition of oral methylene blue transformed the clinical and laboratory response observed in patients. Once the revised protocol was fully established, Dr. Hepburn was able to document viral clearance and symptomatic recovery within 72 hours in most cases.
The clinical experience was remarkable, with the treatment approach contributing to the successful recovery of many seriously ill patients and, potentially saved numerous lives.
The resulting clinical data were subsequently published in the scientific literature.
From Treating Infections to a More Proactive Approach
Although Dr. Hepburn continues to support patients experiencing acute viral illnesses, the focus at Luminnova Health has progressively expanded beyond treating infections once they occur.
An important question emerged from this experience:
Could the same knowledge and technologies be used more proactively—to reduce vulnerability to infection, provide practical protection during periods of increased exposure, and enable a faster response when symptoms first appear?
This thinking led to the development of the Luminnova ImmuneDefense™ Program.
Rather than relying on a single intervention, ImmuneDefense brings together several complementary strategies, informed by scientific research and extensive clinical experience.
Antimicrobial Blue Light: A More Convenient Approach
One of the key components of Luminnova ImmuneDefense™ is antimicrobial blue light (aBL), an innovative, drug-free approach that has shown promising antiviral effects in laboratory studies.
Research has shown that aBL can inactivate a a wide array of viruses, with some laboratory studies reporting reductions of up to 99.9% inactivation (reduction in their ability to cause infection).
What makes this particularly exciting is its potential against a wide range of viruses that may cause respiratory infections. These include the common cold, COVID-19, influenza, respiratory syncytial virus and many others.
From Photodynamic Therapy to a Simpler, More Convenient Approach
Building on her earlier experience with methylene blue photodynamic therapy (PDT), Dr. Hepburn developed a specialized antimicrobial blue light probe for use in the nose and mouth.
Unlike the original PDT approach, which required the application of topical methylene blue followed by light treatment, the aBL probe does not require methylene blue, making the process considerably simpler, cleaner and more convenient.
How the aBL Probe Fits Into ImmuneDefense™
We have incorporated the portable antimicrobial blue light probe into the ImmuneDefense™ Program as an important part of our ImmuneDefense strategies.
The probe is designed for convenient use in the nose and throat, where many respiratory viruses first enter the body and begin multiplying. Its compact, portable design means it can be kept readily available at home or taken when traveling.
This reflects one of the central principles of ImmuneDefense™: being prepared to act early, rather than waiting until an infection becomes established.
Supporting the Body’s Natural Defenses
ImmuneDefense also recognizes that the body’s ability to respond effectively to infection depends on more than direct antiviral interventions.
An important part of the program therefore involves identifying and addressing factors that may compromise normal immune function.
This includes optimizing vitamin D status, supporting appropriate nutritional and metabolic health, and implementing other individualized measures intended to place the body in the best possible position to respond to infectious challenges.
Targeted Antiviral Strategies
In addition to these foundational measures, the program incorporates selected antiviral strategies according to individual circumstances and the stage of potential infection.
Ivermectin is often used as an inexpensive proactive antiviral measure during periods of increased exposure.
Oral methylene blue, however, has become our preferred intervention once symptoms of viral illness have developed.
Over more than five years of clinical experience, Dr. Hepburn has observed consistently impressive responses to oral methylene blue, particularly in the rapid reduction of symptoms and acceleration of recovery.
Its introduction into the COVID-19 treatment protocol represented a major advance in her clinical approach, and subsequent experience has reinforced its importance in the management of many acute viral illnesses.
For Dr. Hepburn, oral methylene blue has been a genuine game changer.
HOW IMMUNEDEFENSE™ WORKS
A Personalized Approach to Viral Infection Preparedness
The clinical experience and innovations described above form the foundation of the Luminnova ImmuneDefense™ Program.
What began as an effort to develop more effective and accessible treatments during the COVID-19 pandemic has evolved into a comprehensive approach focused on helping individuals prepare for viral infections, rather than waiting until illness develops.
ImmuneDefense™ is designed to help you prepare in advance, optimize the foundations of normal immune function, and have a personalized strategy ready when the risk of viral infection increases or symptoms first appear.
Rather than offering a one-size-fits-all supplement or treatment package, we begin by understanding your individual health, nutritional status, medications, risk factors, previous experience with viral infections and personal preferences.
From there, we develop a practical, physician-reviewed strategy that combines nutritional optimization, proactive protection during higher-risk exposure, and individualized plans for early or established viral illness.
An important feature of ImmuneDefense™ is that your assessment and preparation take place while you are well. This allows relevant safety investigations and medication reviews to be completed in advance, reducing uncertainty and potentially avoiding delays when illness occurs.
The program begins with a comprehensive FOUNDATION consisting of three essential stages—ASSESS, RESTORE and MAINTAIN. Building on this foundation, ImmuneDefense™ offers three progressive program tiers, each providing an additional level of preparedness, individualized treatment planning and guidance to help you respond effectively to potential viral exposure or illness.
THE IMMUNEDEFENSE™ PROGRAM
FOUNDATION — Included in Every Program
ASSESS → RESTORE → MAINTAIN
Every ImmuneDefense™ program begins with a comprehensive assessment, correction of important nutritional deficiencies where appropriate, and a personalized strategy for maintaining the foundations of immune health.
1. ASSESS
Understand Your Individual Starting Point
Every participant begins by completing a comprehensive health questionnaire.
This helps us understand your:
Current health and relevant medical conditions
Weight and metabolic health
Vitamin D status and recent laboratory results
Current medications and supplements
Allergies and previous medication reactions
Previous viral infections and recovery
Relevant risk factors and exposure patterns
Nutritional considerations
Individual needs, concerns and preferences
Your questionnaire is reviewed by a physician, who prepares a detailed, personalized evaluation and recommendations.
Depending on your medical history and the level of preparedness you select, additional investigations may be recommended.
For individuals who may be candidates for oral methylene blue, G6PD testing is recommended in advance, together with a review of medications and potential contraindications.
Other investigations, such as a complete blood count or targeted metabolic testing, may be recommended when clinically appropriate.
The aim is to complete important assessments before they become urgent, while avoiding unnecessary investigations.
The objective is simple: understand your starting point before deciding what you need.
2. RESTORE
Optimizing the Foundations of Immune Health
Your immune system relies on much more than the ability to fight infections. It must recognize threats, coordinate an effective response, regulate inflammation and support recovery—all while protecting your body’s own healthy tissues.
Vitamin D plays a remarkably important role in these processes. Beyond its familiar role in bone health, vitamin D helps regulate immune cell activity, supports antimicrobial defenses and influences the body’s inflammatory response.
Research has linked low vitamin D levels with increased susceptibility to respiratory infections, more severe outcomes from certain infections, autoimmune diseases and several types of cancer. These findings highlight the importance of identifying and correcting vitamin D deficiency.
Vitamin D does not work in isolation. Magnesium, vitamin K2 and vitamin A each have important complementary roles and are also prioritized in our ImmuneDefense foundational supplement package.
Where vitamin D levels are particularly low, calcifediol may offer an important advantage by restoring circulating vitamin D levels significantly more rapidly than conventional vitamin D3.
Despite our abundant sunshine in the Bahamas, we are finding that the vast majority of patients tested have inadequate and most frequently very low vitamin D levels. This is one reason why individualized vitamin D assessment and optimization form such an important part of the Luminnova ImmuneDefense™ approach.
Our RESTORE strategy focuses on identifying nutritional deficiencies, correcting them appropriately and establishing a strong foundation for long-term immune health.
We strongly encourage you to explore our dedicated educational guide, which explains why vitamin D and its supporting nutrients deserve far greater attention—not only in antiviral immune defense, but also in cancer and autoimmune health.
Explore: Vitamin D & Immune Health — Antiviral Defense, Cancer and Autoimmune Disease
The guide covers the scientific findings, the importance of related nutrients, the potential advantages of calcifediol and practical considerations for maintaining healthy vitamin D status.
3. MAINTAIN
Support Long-Term Nutritional and Metabolic Health
Following RESTORE, patients continue their individualized nutritional foundation, with vitamin D3, K2 and magnesium adjusted according to their needs.
The goal is to maintain an appropriate nutritional and metabolic environment while keeping the daily routine straightforward and sustainable.
THE THREE IMMUNEDEFENSE™ PROGRAM TIERS
Building on the FOUNDATION, ImmuneDefense™ offers three optional program tiers. Each successive tier incorporates the preceding components, together with a more detailed physician analysis of questionnaire responses, expanded individualized treatment planning and additional guidance and instructions.
TIER 1 — FOUNDATION & PROTECT
Tier 1 includes all three FOUNDATION stages—ASSESS, RESTORE and MAINTAIN—together with proactive measures intended for periods of increased viral exposure.
PROTECT
Prepare for Periods of Increased Viral Exposure
Certain situations increase the likelihood of exposure to respiratory viruses, including air travel, conferences, crowded environments and close contact with individuals who are unwell.
The PROTECT component provides a practical preparedness package intended for use during these higher-risk periods.
The proposed package includes:
Antimicrobial Blue Light (aBL) Probe: Designed for convenient self-administration, allowing brief treatment of the nose and throat as soon as possible following potential exposure. Preventative treatments take only a few minutes and can be performed immediately after - or even during high-risk exposure.
Hypochlorous Acid (HOCl) Spray: A gentle yet highly effective topical antiseptic formulated for oral and nasal use. While aBL treatment is focused primarily on the throat, HOCl spray provides broader coverage throughout the mouth.
Ivermectin tablets: A convenient once-daily dosing proactive antiviral regimen, initiated shortly before anticipated high-risk exposure, continued throughout the exposure period, and maintained for a few days afterward.
Our clinical experience with proactive strategies has been particularly encouraging among elderly individuals with increased vulnerability to infection and frequent travelers who previously experienced recurrent respiratory illnesses.
These observations have helped shape the ImmuneDefense™ approach.
TIER 2 — FOUNDATION & PROTECT + RESPOND EARLY
Tier 2 includes everything in Tier 1, together with a more detailed physician analysis of questionnaire responses, expanded individualized treatment planning and additional instructions for responding promptly when symptoms do appear.
RESPOND EARLY
Be Ready to Act When Symptoms First Appear
Although our clinical experience with the measures included in the PROTECT protocol has been extremely encouraging, these measures cannot guarantee that symptoms of an acute upper respiratory viral illness will not develop. Breakthrough illness may occur for several reasons, including delays in initiating protective measures, particularly heavy viral exposure, or other individual factors that influence susceptibility to infection.
The RESPOND EARLY component therefore provides an additional level of preparedness, ensuring that an individualized treatment plan and appropriate supplies are available should symptoms develop despite proactive protective measures.
One of the central principles of ImmuneDefense™ is that patients should not have to begin researching treatment options or arranging safety investigations only after becoming unwell.
The RESPOND EARLY component is designed to provide a personalized plan and appropriate supplies in advance.
Depending on individual suitability, the proposed strategy may include:
Oral methylene blue capsules: Oral methylene blue is the cornerstone of our treatment for acute viral infections provided that there are no contraindications to its use. We normally observe marked symptom improvements even within a few hours of the first dose. The aim is to have methylene blue on hand for early intervention. You will be given detailed personalized treatment instructions based on your questionnaire responses.
Calcifediol: The proposed calcifediol strategy reflects our clinical approach to supporting vitamin D status during active viral illness which places extra demand on vitamin D stores. Our patients frequently report that a brief calcifediol boost appears to produce a consistent improvement in their clinical response.
Zinc lozenges: Zinc supports normal immune function and has recognized antiviral properties. When dissolved slowly in the mouth, zinc lozenges may help inhibit viral activity and replication in the mouth and throat. Research suggests that starting zinc lozenges at the earliest signs of illness may shorten the duration of upper respiratory illness, making them a potentially useful additional measure during periods of increased viral exposure or early infection.
Continued use of appropriate measures from the PROTECT component, including the aBL probe.
Treatment with the aBL probe at the outset of exposure has a far greater effect on viral inactivation than treatment initiated several hours or days later, due to the exponential rate of viral replication.
The longer the delay between initial exposure and treatment, the less likely the aBL probe will be able to clear the full viral load. Furthermore, over a period of hours to days, viruses are increasingly likely to have spread beyond their initial points of entry.
However, continued use of the aBL probe may still be beneficial at this stage because of its additional intrinsic photodynamic effect. This effect may potentially help “train your immune system,” promoting a better-coordinated response to the virus, even after it has spread beyond the initial points of entry.
The objective is to ensure that each patient has an individualized response plan ready before symptoms develop, together with clear instructions on when additional medical assessment is necessary.
TIER 3 — FOUNDATION & PROTECT + RESPOND EARLY + ESCALATE
Tier 3 includes everything in Tiers 1 and 2, together with the most extensive physician analysis of questionnaire responses, additional individualized treatment planning and detailed instructions for managing more significant or established illness.
ESCALATE
Additional Support When Viral Infection Is Already Established
Our clinical experience has consistently reinforced the importance of prevention and timely intervention.
In our experience, established infections requiring more intensive treatment are most commonly encountered when preventive or early-response measures have not been used, or when treatment has been delayed.
Other factors may also increase your vulnerability, including high-risk exposures or temporary reductions in immune defenses associated with stress, inadequate sleep or other influences.
The ESCALATE component is therefore particularly relevant for patients who wish to have an individualized plan in place in advance, should a viral infection become established despite preventive or early-response measures.
Because timely intervention is important, a key advantage of ImmuneDefense™ is having your personalized treatment plan and appropriate supplies available before they are needed. This allows you to begin previously approved measures promptly, without unnecessary delays in obtaining supplies or arranging investigations.
The proposed strategy builds upon the earlier components and is individualized according to your health assessment, medical history and clinical circumstances.
Early Medical Guidance Is Strongly Recommended
Although your ImmuneDefense™ plan is prepared in advance, we strongly recommend arranging a telehealth consultation with Luminnova Health as early as possible if the ESCALATE stage becomes necessary.
This allows your physician to assess the nature and severity of your illness, review the measures you have already taken, confirm the most appropriate treatment strategy and make timely adjustments where necessary. Additional individualized treatment options may also be offered at this stage where clinically indicated.
The objective is not to wait until symptoms become persistent or severe before seeking advice, but to combine the benefits of advance preparation with early, individualized medical guidance.
Previously approved early-response measures can be started while arranging your consultation, provided they remain appropriate to your circumstances. More intensive treatment should be undertaken with physician guidance.
Telehealth Consultation Fees
Telehealth consultations during ESCALATE are provided as an additional service and incur a separate consultation fee.
Because it is not possible to anticipate whether or when an acute illness will occur, or the level of medical support that may be required, these consultations are not included in the initial ImmuneDefense™ program fee.
This approach ensures that additional medical support is available when needed, without requiring every participant to pay in advance for services they may never require.
PREPARED IN ADVANCE. PERSONALIZED FOR YOU.
A distinguishing feature of ImmuneDefense™ is that the assessment, preparation and organization of your supplies take place before they are needed.
Your assessment begins with a comprehensive online health questionnaire, which you can complete at your convenience. Your responses, medical history, medications, supplements and relevant laboratory results are then reviewed by a physician, who prepares your personalized evaluation and recommendations remotely.
Your personalized report identifies which components are appropriate for you, which require additional safety screening and which should not be used because of your medical circumstances.
The intention is to provide a clear, practical plan that reduces uncertainty when exposure occurs or symptoms develop.
Physician Support and Acute Illness Consultations
Your initial ImmuneDefense™ assessment and personalized report are included in the program evaluation.
The program is designed to minimize the need for repeated consultations by addressing important questions and safety considerations in advance.
However, consultations for an acute viral illness are not included in the standard package and are charged separately.
If you develop symptoms requiring medical assessment, experience an unexpected reaction, or need changes to your treatment plan, an additional consultation may be necessary.
The preparedness plan does not replace medical evaluation when illness is severe, worsening or otherwise concerning.
Be Prepared | Stay Resilient | Support Recovery
Luminnova ImmuneDefense™
A personalized, physician-guided approach to viral infection preparedness.